Morlock Stephen

Avg. Two Year Performance

(89%) Avg. Purchase Return
(37%) Compound
97% Avg. Sale Return
40% Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return2%(26%)(51%)(71%)(89%)
Purchase Success Rate1 of 21 of 20 of 20 of 20 of 2
Average Sale Return5%27%59%92%97%
Sale Success Rate1 of 11 of 11 of 11 of 11 of 1

BioPharmX Corporation

Drugs » Biotechnology

Director:

Holdings: 0 shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--